非小细胞肺癌患者外周血hTERT mRNA水平检测的临床意义-东南大学学报医学版

非小细胞肺癌患者外周血hTERT mRNA水平检测的临床意义

单位：1. 蚌埠医学院第一附属医院老年病科, 安徽蚌埠 233003;
2. 安徽呼吸系病临床基础省级实验室, 安徽蚌埠 233004

分类号：R734.2

出版年·卷·期（页码）：2017·36·第二期（217-221）

摘要：

目的：探讨非小细胞肺癌（NSCLC）发展与外周血端粒酶逆转录酶（hTERT）表达的相关性。方法：采用Real-time PCR技术检测114例NSCLC患者和35例肺部良性病变患者外周血hTERT mRNA表达水平，比较二者之间的差异并分析。结果：检测结果显示，肺鳞癌Ⅰ~Ⅳ期hTERT mRNA表达量分别为（0.134±0.018）×10^-3、（0.185±0.044）×10^-3、（0.576±0.267）×10^-3、（3.409±2.544）×10^-3，Ⅰ、Ⅱ期之间差异无统计学意义（P>0.05），其余各组之间差异有统计学意义（P<0.05）；肺腺癌Ⅰ~Ⅳ期hTERT活性分别为（0.156±0.006）×10^-3、（0.220±0.052）×10^-3、（0.630±0.282）×10^-3、（3.230±2.245）×10^-3，Ⅰ、Ⅱ期之间差异无统计学意义（P>0.05），其余各组之间差异有统计学意义（P<0.05）；同期鳞癌与腺癌之间差异无统计学意义（P>0.05）；肺部良性病变组外周血hTERT mRNA表达水平为（0.042±0.017）×10^-3，与肺癌组之间存在显著性差异（P<0.05）。结论：NSCLC患者外周血hTERT mRNA表达显著升高，并与NSCLC临床分期正相关，提示其可作为肺癌诊断和临床分期的有益参考，但与NSCLC的病理类型无关。

Objective: To discuss the correlation between human telomerase reverse transcriptase (hTERT) activity in peripheral blood and the development of non-small cell lung cancer(NSCLC). Methods: 114 cases of NSCLC and 35 cases of lung benign lesions were collected. hTERT mRNA expression of the patients with NSCLC or lung benign lesions were determined and analyzed by the real-time PCR. Results: The expressions of hTERT mRNA in peripheral blood of Ⅰ-Ⅳ clinical stages of lung squamous carcinoma were (0.134±0.018)×10^-3, (0.185±0.044)×10^-3,(0.576±0.267)×10^-3 and (3.409±2.544)×10^-3, excepting clinical stage Ⅰand Ⅱ,the differences among other groups were statistically significant(P<0.05); The expressions of hTERT mRNA in peripheral blood of Ⅰ-Ⅳ clinical stages of lung adenocarcinoma were(0.156±0.006)×10^-3, (0.220±0.052)×10^-3, (0.630±0.282)×10^-3, (3.230±2.245)×10^-3,excepting clinical stage Ⅰand Ⅱ,the differences among other groups were statistically significant(P<0.05); in the same clinical stage, the differences between squamous carcinoma and adenocarcinoma were not statistically significant(P>0.05). The level of hTERT mRNA in peripheral blood of lung benign lesions was (0.042±0.017)×10^-3, and the difference between lung benign lesions and NSCLC was significant (P<0.05). Conclusion: The level of hTERT mRNA of NSCLC increase significantly and it is positively associated with clinical stages, which also implies that the expression of hTERT mRNA may be benefit to make the diagnose and clinical stages of NSCLC, but it is not associated with clinical pathological type.

参考文献：

[1] XING Y L,LIU F,LIN J C,et al.Case-control study on impact of the telomerase reverse transcriptase gene polymorphism and additional single nucleotide polymorphism (SNP)-SNP interaction on non-small cell lung cancers risk in Chinese Han population[J].J Clin Lab Anal,2016,30(6):1071-1077.
[2] FRINK R E,PEYTON M,SCHILLER J H,et al.Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner[J].Oncotarget,2016,7(22):31639-31651.
[3] 王晶.第一代靶向药物治疗晚期 NSCLC 的临床观察[J].现代医学,2016,43(11):1423-1424.
[4] SUN Y,YANG C,CHEN J,et al.Overexpression of WDR79 in non-small cell lung cancer is linked to tumour progression[J].J Cell Mol Med,2016,20(4):698-709.
[5] 李献文,仇铁峰,丁明,等.hTERT mRNA 在肺癌中的作用[J].癌症进展,2016,14(1):71-73.
[6] LIU T J,ULLENBRUCH M,CHOI Y Y,et al.Telomerase and telomere length in pulmonary fibrosis[J].Am J Resp Cell Mol,2013,49(2):260-268.
[7] KUBICA K D,ZIOB M Z,BRULINSKI K,et al.Telomerase activity in non-small cell lung cancer[J].Kardiochir Torakochi, 2016,13(1):15-20.
[8] CHA N,LI X Y,ZHAO Y J,et al.hTERT gene amplification and clinical significance in pleural effusions of patients with lung cancer[J].Clin Lung Cancer,2012,13(6):494-499.
[9] PELLATT A J,WOLFF R K,HERRICK J,et al.TERT's role in colorectal carcinogenesis[J].Mol Carcinogen,2013,52(7):507-513.
[10] DING M,LI X,QIU T.Combination of multiple gene markers to detect circulating tumor cells in the peripheral blood of patients with non-small cell lung cancer using real-time PCR[J].Genet Mol Res,2015,14(4):13033-13040.
[11] DORSEY J F,KAO G D,MACARTHUR K M,et al.Tracking viable circulating tumor cells(CTCs) in the peripheral blood of non-small cell lung cancer(NSCLC) patients undergoing definitive radiation therapy:pilot study results[J].Cancer,2015,121(1):139-149.
[12] 李红梅,滑峰,赵诚,等.诱导痰、胸水和纤维支气管镜活组织端粒酶活性的联合检测对肺癌的诊断价值[J].中国肺癌杂志,2010,13(2):128-131.
[13] 杨斌,马莉,岳强,等.非小细胞肺癌患者手术和辅助化疗期间人端粒酶逆转录酶mRNA的表达变化及临床意义[J].中国药物与临床,2016,16(1):67-69.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录